



# STIC Search Report

## Biotech-Chem Library

STIC Database Tracking Number: 152919

**TO: Kevin Weddington**  
**Location: 3 C 70**  
**Art Unit: 1614**  
**Thursday, May 12, 2005**

**Case Serial Number: 10/743997**

**From: Mary Jane Ruhl**  
**Location: Biotech-Chem Library**  
**Remsen 1-A-62**  
**Phone: 571-272-2524**

**maryjane.ruhl@uspto.gov**

### Search Notes

Examiner Weddington,

Here are the results for your recent search request.

Please feel free to contact me if you have any questions about these results.

Thank you for using STIC services. We appreciate the opportunity to serve you.

Sincerely,

Mary Jane Ruhl  
Technical Information Specialist  
STIC  
Remsen 1-A-62  
Ext. 22524





# STIC SEARCH RESULTS FEEDBACK FORM

## Biotech-Chem Library

Questions about the scope or the results of the search? Contact ***the searcher or contact:***

Mary Hale, Information Branch Supervisor  
Remsen Bldg. 01 D86  
571-272-2507

## Voluntary Results Feedback Form

➤ I am an examiner in Workgroup:  Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature  
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



REM-3070

152919  
Access DB#

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: K. Weddington Examiner #: 68082 Date: 5-9-05  
Art Unit: 1614 Phone Number: 301-272-0587 Serial Number: 101743, 997  
Mail Box and Bldg/Room Location: \_\_\_\_\_ Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: \_\_\_\_\_

Inventors (please provide full names): Yukio Nihei

Earliest Priority Filing Date: \_\_\_\_\_

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

A composition comprising

1) AC-7700

2) Dexamethasone

RECEIVED  
MAY - 9 2005  
(STIC)

## STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: _____	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: _____	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: _____	Other _____	Other (specify) _____

PTO-1590 (1-2000)

=> d his ful

FILE 'HCAPLUS' ENTERED AT 16:12:54 ON 12 MAY 2005

E NIHEI YUKIO/AU  
L16 17 SEA ABB=ON "NIHEI YUKIO"/AU  
E MORINAGA YOSHIHIRO/AU  
L17 24 SEA ABB=ON "MORINAGA YOSHIHIRO"/AU  
E SUZUKI MANABU/AU  
L18 128 SEA ABB=ON "SUZUKI MANABU"/AU  
E SUGA YASUYO/AU  
L19 17 SEA ABB=ON "SUGA YASUYO"/AU  
L20 3 SEA ABB=ON L16 AND L17 AND L18 AND L19  
L21 ANALYZE L20 1-3 CT : 12 TERMS

FILE 'REGISTRY' ENTERED AT 16:17:02 ON 12 MAY 2005

L22 1 SEA ABB=ON AC 7700/CN  
L23 1 SEA ABB=ON DEXAMETHASONE/CN

FILE 'HCAPLUS' ENTERED AT 16:17:25 ON 12 MAY 2005

L24 1 SEA ABB=ON L22 AND L23  
L25 1 SEA ABB=ON (L22 OR AC7700 OR AC(W)7700) AND (L23 AND ?DEXAMETH  
ASONE?) *1 cit from OA Plus*

FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO, JICST-EPLUS' ENTERED AT 16:27:07 ON  
12 MAY 2005

L26 0 SEA ABB=ON L25 *0 cit's from other d.b's*

=> d que stat 1 25  
 'L' IS NOT VALID HERE  
 For an explanation, enter "HELP DISPLAY QUERY".

=> d que stat 125  
 L22 1 SEA FILE=REGISTRY ABB=ON AC 7700/CN  
 L23 1 SEA FILE=REGISTRY ABB=ON DEXAMETHASONE/CN  
 L25 1 SEA FILE=HCAPLUS ABB=ON (L22 OR AC7700 OR AC(W)7700) AND (L23  
 AND ?DEXAMETHASONE?)

=> d ibib abs 125 1-1

L25 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2003:5807 HCAPLUS  
 DOCUMENT NUMBER: 138:33328  
 TITLE: Antitumor agents  
 INVENTOR(S): Nihei, Yukio; Morinaga, Yoshihiro; Suzuki, Manabu;  
 Suga, Yasuyo  
 PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan  
 SOURCE: PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000290	A1	20030103	WO 2002-JP6260	20020624
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1407784	A1	20040414	EP 2002-738789	20020624
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004192621	A1	20040930	US 2003-743997	20031224
PRIORITY APPLN. INFO.:			JP 2001-191067	A 20010625
			WO 2002-JP6260	W 20020624

AB Antitumor agents with a combined use of a tubulin polymerization inhibitor having  
 an antitumor activity with an antiinflammatory agent. These two active ingredients may be contained in a single preparation Alternatively, two preps. containing the resp. ingredients to be administered sep. may be combined with each other. In case of using a tubulin polymerization inhibitor as  
 the active ingredient of an antitumor agent, the toxicity of the tubulin polymerization inhibitor at the pharmaceutically ED can be largely relieved while  
 maintaining the pharmaceutically ED and the fatal dose can be increased to thereby broaden the safety range. Moreover, antitumor methods (treatment methods for the treatment, improvement, inhibition of progress, prevention, etc. of tumor in vivo), use of the above two active

ingredients in drugs such as antitumor agents, and combined use of the above two active ingredients as drugs such as antitumor agents either simultaneously or sep.

REFERENCE COUNT: 20

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

*Inventor Search*

Weddington 10/743,997

12/05/2005

=> d ibib abs ind l20 1-3

L20 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:315042 HCAPLUS

DOCUMENT NUMBER: 139:159593

TITLE: Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo

AUTHOR(S): Morinaga, Yoshihiro; Suga, Yasuyo; Ehara, Sumiko; Harada, Katsuhiko; Nihei, Yukio; Suzuki, Manabu

CORPORATE SOURCE: Pharmaceutical Research Laboratories, Ajinomoto Co., Inc., Kawasaki, 210-8681, Japan

SOURCE: Cancer Science (2003), 94(2), 200-204

CODEN: CSACCM; ISSN: 1347-9032

PUBLISHER: Japanese Cancer Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The in vivo combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin (CDDP) was examined. The combination of AC-7700 and CDDP increased antitumor activity against murine colon 26 tumor in mice and cured the mice. This combination effect was found over wide dosage ranges of AC-7700 (20-80 mg/kg) and CDDP (2.5-5 mg/kg). Moreover, this combination augmented antitumor activity against murine S180 and M109 tumors, and human LX-1 and LS180 tumor xenografts in mice. The effect was the strongest when AC-7700 and CDDP were administered simultaneously. To study this combination effect, we measured the concns. of CDDP in tumors, plasma and kidneys of the mice with colon 26 tumor. In the combination with AC-7700, the concentration of CDDP in the tumors increased from 0.5 to 96

h after administration, but did not change or decrease in plasma or kidneys. Against human LS180 xenografts in mice, the combination similarly increased that concentration of CDDP in the tumors. These results suggest that AC-7700 may specifically augment the accumulation of CDDP in tumors, and thus has the potential to be useful in combination chemotherapy with CDDP.

CC 1-6 (Pharmacology)

ST antitumor AC7700 cisplatin combination therapy colon cancer

IT Intestine, neoplasm

(colon; combination effect of AC-7700 and cisplatin against murine and human tumors)

IT Antitumor agents

Drug interactions

Human

(combination effect of AC-7700 and cisplatin against murine and human tumors)

IT 15663-27-1, Cisplatin

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)

(combination effect of AC-7700 and cisplatin against murine and human tumors)

IT 253426-24-3, AC-7700

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(combination effect of AC-7700 and cisplatin against murine and human tumors)

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:5807 HCAPLUS  
 DOCUMENT NUMBER: 138:33328  
 TITLE: Antitumor agents  
 INVENTOR(S): Nihei, Yukio; Morinaga, Yoshihiro;  
 Suzuki, Manabu; Suga, Yasuyo  
 PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan  
 SOURCE: PCT Int. Appl., 32 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000290	A1	20030103	WO 2002-JP6260	20020624
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1407784	A1	20040414	EP 2002-738789	20020624
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004192621	A1	20040930	US 2003-743997	20031224
PRIORITY APPLN. INFO.:			JP 2001-191067	A 20010625
			WO 2002-JP6260	W 20020624

AB Antitumor agents with a combined use of a tubulin polymerization inhibitor having  
 an antitumor activity with an antiinflammatory agent. These two active ingredients may be contained in a single preparation. Alternatively, two prepsns. containing the resp. ingredients to be administered sep. may be combined with each other. In case of using a tubulin polymerization inhibitor  
 as  
 the active ingredient of an antitumor agent, the toxicity of the tubulin polymerization inhibitor at the pharmaceutically ED can be largely relieved  
 while

maintaining the pharmaceutically ED and the fatal dose can be increased to thereby broaden the safety range. Moreover, antitumor methods (treatment methods for the treatment, improvement, inhibition of progress, prevention, etc. of tumor in vivo), use of the above two active ingredients in drugs such as antitumor agents, and combined use of the above two active ingredients as drugs such as antitumor agents either simultaneously or sep.

IC ICM A61K045-08

ICS A61P035-00

CC 1-6 (Pharmacology)

Section cross-reference(s): 2, 63

ST antitumor tubulin polymn inhibitor antiinflammatory toxicity

IT Anti-inflammatory agents

Antitumor agents

Drug delivery systems

Drug interactions

Drug toxicity



## Neoplasms

(tubulin polymerization inhibitors and steroidal and non-steroidal antiinflammatory agents as antitumor drugs)

## IT Tubulins

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(tubulin polymerization inhibitors and steroidal and non-steroidal antiinflammatory agents as antitumor drugs)

## IT Flavonoids

Steroids, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(tubulin polymerization inhibitors and steroidal and non-steroidal antiinflammatory agents as antitumor drugs)

## IT Alkaloids, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(vinca; tubulin polymerization inhibitors and steroidal and non-steroidal antiinflammatory agents as antitumor drugs)

IT 50-02-2D, Dexamethasone, derivs. 50-23-7, Cortisol 50-24-8,  
Prednisolone 53-33-8, Paramethasone 64-86-8D, Colchicine, derivs.  
67-73-2 83-43-2, Methylprednisolone 124-94-7, Triamcinolone  
362-07-2, 2-Methoxyestradiol 378-44-9, Betamethasone 518-28-5D,  
Podophyllotoxin, derivs. 588-59-0D, Stilbene, derivs. 2392-39-4,  
Dexamethasone sodium phosphate 253426-24-3, AC 7700  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(tubulin polymerization inhibitors and steroidal and non-steroidal antiinflammatory agents as antitumor drugs)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:659251 HCAPLUS

DOCUMENT NUMBER: 131:281555

TITLE: Antitumor agents

INVENTOR(S): Morinaga, Yoshihiro; Nihei, Yukio;  
Suga, Yasuyo; Suzuki, Manabu;  
Ohishi, Kazuo; Okano, Akira

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951246	A1	19991014	WO 1999-JP1633	19990329
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2326761	AA	19991014	CA 1999-2326761	19990329

AU 9929607	A1	19991025	AU 1999-29607	19990329
AU 747599	B2	20020516		
BR 9909393	A	20001226	BR 1999-9393	19990329
EP 1068870	A1	20010117	EP 1999-910779	19990329
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NZ 507221	A	20030429	NZ 1999-507221	19990329
RU 2215525	C2	20031110	RU 2000-127751	19990329
NO 2000004911	A	20001204	NO 2000-4911	20000929
ZA 2000005335	A	20010619	ZA 2000-5335	20001002
US 2002193434	A1	20021219	US 2002-156105	20020529
US 2002193362	A1	20021219	US 2002-166763	20020612
PRIORITY APPLN. INFO.:			JP 1998-108708	A 19980403
			JP 1998-229843	A 19980814
			WO 1999-JP1633	W 19990329
			US 2000-678406	A1 20001003

AB Antitumor agents containing as the active ingredients stilbene derivs. and platinum coordination compds. Owing to the combined use of these two types of active ingredients, these agents are expected as useful as highly safe antitumor agents showing a synergistically improved antitumor activity. When used together with the above platinum coordination compds., the antitumor activity inherent to the stilbene derivs. is further enhanced to give antitumor agents having improved efficaciousness which are particularly adequate for treating malignant tumors. Further, utilization of these active ingredients as drugs or for therapy, etc. as well as methods therefor are provided.

IC ICM A61K033-24  
ICS A61K031-165; A61K031-275; A61K031-28; A61K031-395

CC 1-6 (Pharmacology)  
Section cross-reference(s): 63

ST stilbene deriv platinum compd antitumor

IT Antitumor agents  
(antitumor agents containing stilbene derivs. and platinum coordination compds.)

IT Drug delivery systems  
(injections; antitumor agents containing stilbene derivs. and platinum coordination compds.)

IT Tubulins  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(polymerization; antitumor agents containing stilbene derivs. and platinum coordination compds. effect on)

IT Drug interactions  
(synergistic; antitumor agents containing stilbene derivs. and platinum coordination compds.)

IT 588-59-0D, Stilbene, derivs. 7440-06-4D, Platinum, coordination compds., biological studies 15663-27-1, Cisplatin 41575-94-4, Carboplatin 95734-82-0, Nedaplatin 162705-07-9 162705-10-4 181816-48-8  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antitumor agents containing stilbene derivs. and platinum coordination compds.)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT